Clinical trials: CRC, Colorectal Cancer
Colorectal Cancer
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa (SOT101) in combination with cetuximab in RAS wild-type colorectal cancer.
- Trial name
- NCT05619172
- Testing
- Nanrilkefusp alfa, Cetuximab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 16 people
- Sponsor
- SOTIO Biotech AG
Colorectal Cancer
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
In this Phase II study the investigators plan to determine the overall response rate (ORR) of the combination of FOLFOXIRI plus panitumumab as first-line treatment of patients with liver-only metastatic KRAS wild-type colorectal…
- Trial name
- NCT01226719
- Testing
- Panitumumab, Oxaliplatin, Irinotecan
- Where
- 15 sites in United States
- Volunteers
- 15 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer
A Smartphone-Based Intervention to Improve Colorectal Cancer Screening in African American Men
The goal of this clinical trial is to test a new smartphone-based program designed to help African American men get screened for colorectal cancer (CRC).
- Trial name
- NCT06052202
- Testing
- CRC mHealth, Control
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- ISA Associates, Inc.
Health Behavior, Colorectal Cancer
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer…
- Conditions
- Health Behavior, Colorectal Cancer, Influenza, COVID-19
- Trial name
- BENEFIT-C (NCT06124131)
- Testing
- Financial incentive for colorectal cancer screening, Financial incentive for flu shot, Financial incentive for COVID-19 shot
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tulane University
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Colorectal Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00112918
- Testing
- Bevacizumab, Capecitabine, 5-Fluorouracil (5-FU)
- Where
- United States
- Volunteers
- 3,451 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Non-small Cell Lung Cancer
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive…
- Conditions
- Solid Tumors, Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer
- Trial name
- NCT03473925
- Testing
- Navarixin, Pembrolizumab
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
This is an open label, single-arm, Phase 2 trial to evaluate the anti-tumor activity, safety, and tolerability of Pembrolizumab in combination with azacitidine in subjects with chemo-refractory mCRC without any further standard…
- Trial name
- NCT02260440
- Testing
- Pembrolizumab, Azacitidine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Anuradha Krishnamurthy
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in…
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
- Trial name
- NCT00748215
- Testing
- calcium aluminosilicate anti-diarrheal
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer
Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
Although treatment for metastatic colorectal cancer has improved significantly over the recent years, it still remains a significant health problem representing the leading cancer by incidence in the United States of America.
- Trial name
- NCT00199797
- Testing
- Oxaliplatin, 5-Fluorouracil, Leucovorin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Ludwig Institute for Cancer Research
Colon Cancer, Precancerous Condition
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
This randomized phase II trial is studying how well aspirin works in preventing colorectal cancer in patients at increased risk of colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Conditions
- Colon Cancer, Precancerous Condition, Rectal Cancer
- Trial name
- NCT00468910
- Testing
- acetylsalicylic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Improving Colorectal Cancer Screening in Racially Diverse Zip Codes Using Navigation and Machine Learning (PCSNaP)
The overarching goal of the "PCSNaP" Research Study is to support the Abramson Cancer Center (ACC) of the University of Pennsylvania in carrying out its mission to increase colorectal cancer (CRC) screening completion among…
- Trial name
- PCSNaP (NCT05383976)
- Testing
- Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program
- Where
- United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Colorectal Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression.
- Trial name
- NCT00636610
- Testing
- Vismodegib 150 mg, Bevacizumab, Modified FOLFOX
- Volunteers
- 199 people
- Sponsor
- Genentech, Inc.
Colorectal Neoplasm
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
This trial will evaluate the combination treatment of established chemotherapy regimen mFOLFOX6 with Selinexor, an oral Selective Inhibitor Of Nuclear Export, in patients with metastatic Colorectal Cancer.
- Trial name
- SENTINEL (NCT02384850)
- Testing
- Selinexor, Oxaliplatin, 5-FU
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 10 people
- Sponsor
- GSO Global Clinical Research BV
Colorectal Cancer
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
People with colorectal cancer that cannot be cured by surgery are being asked to participate in this study. The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide…
- Trial name
- NCT01051596
- Testing
- Temozolomide, ABT-888
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Colorectal Carcinoma
Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum
58 patients undergoing surgery of the large bowel are divided into two groups. The control group will receive standard care. The intervention group will receive standard care plus optimization of the blood circulation based on…
- Trial name
- HOC (NCT01175317)
- Testing
- Goal-directed fluid optimization, Regimen based on expertise anaesthesist
- Where
- Netherlands
- Volunteers
- 58 people
- Sponsor
- Maastricht University Medical Center
Colorectal Carcinoma, Gastric Adenocarcinoma
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX).
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04430738
- Testing
- tucatinib, trastuzumab, oxaliplatin
- Where
- 27 sites in United States, Japan
- Volunteers
- 40 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Colorectal Cancer, Colorectal Carcinoma
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
- Trial name
- NCT00437268
- Testing
- enzastaurin, irinotecan, cetuximab
- Where
- 20 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
The main purpose of this study is to evaluate the progression-free survival (PFS) in patients receiving S 95005 + bevacizumab (experimental arm) or capecitabine + bevacizumab (control arm) as first-line treatment for unresectable…
- Trial name
- TASCO1 (NCT02743221)
- Testing
- Trifluridine/tipiracil + bevacizumab, Capecitabine + bevacizumab
- Where
- 57 sites in Australia, Belgium and 10 more
- Volunteers
- 154 people
- Sponsor
- Institut de Recherches Internationales Servier